Jutta Heim joins Nuevolution

Nuevolution has appointed Prof Dr Jutta Heim as director and senior scientific advisor to its board of directors.

She brings to the Copenhagen-based small molecule lead discovery company more than 20 years of experiences working for Ciba-Geigy/Novartis.   

She was involved in the development and launch of anti-thrombotic and fibrinolytic products and established Novartis' oncology molecular genetics department.  

Prof Heim served as Novartis' senior scientific expert in molecular biology, was a member of its research management board and finished her time with the company heading the Novartis Lead Discovery Center with worldwide responsibility.  

She has also served as CSO at Swiss biopharma company Basilea Pharmaceutica, which focuses on anti-infectives, inflammation and oncology.  

Most recently Prof Heim was chief technology officer and chief scientific officer at health, wellness and nutrition company Evolva, 2009 to 2013.  

Alex Gouliaev, Nuevolution CEO, said: “Jutta's significant expertise and input has already been well appreciated by management and our board. We are certain that her experience from the industry, broad insight into general drug discovery and, in particular, within oncology will add significant value to the company.”